Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RAPT vs VCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCEL Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

VCEL Overall Winner 6-Pillar Tally: RAPT 0 – 6 VCEL Matrix Metrics: RAPT 3 – 7 VCEL

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas VCEL carries 34.8/100 (SELL) at $57.68 (60.5x Forward P/E, 8.3% operating margin).

  • Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 0.0% operating margin) and revenue trajectory (+26.5% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPT vs VCEL
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67
VCEL NASDAQ Head-to-Head Winner
Vericel Corporation
Biological Products, (No Disgnostic Substances)
$57.68
+1.26% 1D
Market Cap $2.9B
TTM Revenue $324M
Forward P/E 60.5x
Beta / 30D Vol 0.31β · 75% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 34.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 74
RSI-14: 73.9 · SMA20: $47.98 · SMA50: $43.13

6-Pillar Scorecard Institutional Category Breakdown (RAPT 0 – 6 VCEL)

Columns: Metric · RAPT · VCEL
1. Valuation Multiples VCEL
Forward P/E N/M 60.5x
Trailing P/E N/M 90.3x
PEG Ratio N/M N/M
EV / Revenue N/M 9.0x
2. Growth & Scale VCEL
Revenue Growth (YoY) -100.0% +26.5%
Earnings Growth (YoY) +0.0% +170.0%
TTM Revenue (USD) N/A $324M
Market Cap $1.7B $2.9B
3. Profitability & Quality VCEL
Gross Margin N/A 74.5%
Operating Margin 0.0% 8.3%
Net Profit Margin 0.0% 10.3%
Return on Equity (ROE) -85.4% 9.4%
4. Balance Sheet & Cash Flow VCEL
Cash Generation (TTM) N/A $58M
Cash Flow Margin N/A 17.9%
Net Cash / Leverage $9.02 Book/Sh · -85.4% ROE $43M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCEL
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 0.8% (<1st %ile) 44.1% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat VCEL
OpEx & R&D Intensity N/A 66.2% of Rev ($215M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPT (3) vs VCEL (7)
Institutional Metric RAPT VCEL Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.9B Larger Scale VCEL
Trailing P/E Ratio
Valuation
N/M 90.3x Lower Multiple VCEL
Forward P/E Ratio
Valuation
N/M 60.5x Lower Multiple VCEL
Revenue Growth (YoY)
Growth
-100.0% +26.5% Higher Growth VCEL
Operating Margin (TTM)
Profitability
0.0% 8.3% Higher Margin VCEL
Net Profit Margin
Profitability
0.0% 10.3% Higher Margin VCEL
Return on Equity (ROE)
Capital Efficiency
-85.4% 9.4% Higher ROE VCEL
52-Week Range Position
Momentum
100% ($1–$58) 93% ($29–$60) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
-0.02β · 2% Vol 0.31β · 75% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 34.8 / 100 (SELL) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
N/A $324M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.02 Book/Sh · -85.4% ROE) $58M ($43M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +3.8 pp
RAPT: +0.68% · VCEL: -3.12%
3M Horizon RAPT +86.85 pp
RAPT: +74.44% · VCEL: -12.41%
6M Horizon RAPT +113.24 pp
RAPT: +101.95% · VCEL: -11.29%
1Y Horizon RAPT +113.24 pp
RAPT: +101.95% · VCEL: -11.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs VCEL. Trailing 12-month operating profitability (RAPT 0.0% vs VCEL 8.3%) and valuation multiples (RAPT N/M vs VCEL 60.5x Forward P/E) are benchmarked directly in Pillar 4 below.

RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M
VCEL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$324M
Gross Margin74.5%
Op. Margin8.3%
ROE / Fwd P/E9.4% · 60.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCEL SURGE
5d in phase · OBV ACCUMULATION
Current IV 44.1%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VCEL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($215M)
90D Engineering Disclosures 0 Published

Investor FAQ RAPT vs VCEL Key Questions & Quantitative Answers

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas VCEL carries 34.8/100 (SELL) at $57.68 (60.5x Forward P/E, 8.3% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 0.0% operating margin) and revenue trajectory (+26.5% vs. -100.0% YoY).

VCEL leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VCEL at +26.5% YoY revenue growth and +170.0% YoY earnings growth on $324M TTM revenue (74.5% gross margin, 8.3% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus $324M for VCEL. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($215M) (0 disclosures) for VCEL.

VCEL screens cheaper on headline valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VCEL trades at 60.5x Forward P/E, 90.3x Trailing P/E, N/M PEG, and 9.0x EV/Revenue (17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus VCEL (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, VCEL carries 44.1% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.31β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.